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Abstract
The selective serotonin reuptake inhibitor (SSRI) ProzacH (fluoxetine) is the only registered antidepressant to treat
depression in children and adolescents. Yet, while the safety of SSRIs has been well established in adults, serotonin exerts
neurotrophic actions in the developing brain and thereby may have harmful effects in adolescents. Here we treated
adolescent and adult rats chronically with fluoxetine (12 mg/kg) at postnatal day (PND) 25 to 46 and from PND 67 to 88,
respectively, and tested the animals 7–14 days after the last injection when (nor)fluoxetine in blood plasma had been
washed out, as determined by HPLC. Plasma (nor)fluoxetine levels were also measured 5 hrs after the last fluoxetine
injection, and matched clinical levels. Adolescent rats displayed increased behavioral despair in the forced swim test, which
was not seen in adult fluoxetine treated rats. In addition, beneficial effects of fluoxetine on wakefulness as measured by
electroencephalography in adults was not seen in adolescent rats, and age-dependent effects on the acoustic startle
response and prepulse inhibition were observed. On the other hand, adolescent rats showed resilience to the anorexic
effects of fluoxetine. Exploratory behavior in the open field test was not affected by fluoxetine treatment, but anxiety levels
in the elevated plus maze test were increased in both adolescent and adult fluoxetine treated rats. Finally, in the amygdala,
but not the dorsal raphe nucleus and medial prefrontal cortex, the number of PSA-NCAM (marker for synaptic remodeling)
immunoreactive neurons was increased in adolescent rats, and decreased in adult rats, as a consequence of chronic
fluoxetine treatment. No fluoxetine-induced changes in 5-HT1A receptor immunoreactivity were observed. In conclusion, we
show that fluoxetine exerts both harmful and beneficial age-dependent effects on depressive behavior, body weight and
wakefulness, which may relate, in part, to differential fluoxetine-induced neuroplasticity in the amygdala.
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Introduction
Selective serotonin reuptake inhibitors (SSRIs) are among the
most widely prescribed drugs in psychiatry. While numerous trials
have shown robust safety of SSRIs in adults, limited data are
available on their short- and long-term safety in adolescents. Yet,
the number of children for whom anti-depressants are prescribed
has increased during the last decade [1]. Fluoxetine is the only
SSRI registered for treatment of depression in the paediatric
population. Some alarming studies have reported that children
and adolescents may experience increases in suicidal ideation and
behavior, as well as agitation, depression and anxiety [2–6]. A
meta-analysis revealed that the younger the children were the
greater the risk was of suicidal thoughts or attempts [7]. Based on
some of these reports, the Federal Drug Agency and European
Medicines Agency stated in 2004 that SSRIs were contraindicated for
treating depression in children and adolescents. However, in 2006
fluoxetine was approved in children aged 8 years and older for
treatment of moderate to severe depression [8].
Some recent rodent studies have elaborated the human findings.
Mason et al. [9] showed that subchronic fluoxetine treatment (10–
20 mg/kg) during the 5
th week of age had no effect on depression-
like behavior in mice. Also chronic adolescent fluoxetine treatment
(10–18 mg/kg) between 3 and 7 weeks of age did not affect adult
measures of anxiety-, fear- or stress-related behaviors in mice [10].
However, another mouse study reported that adolescent fluoxetine
treatment (7.5–16 mg/kg) at 4–9 weeks of age prevented increased
depression-related immobility in the forced swim test following
maternal separation stress [11]. Further, Oh and colleagues [12]
showed that juvenile mice treated with fluoxetine (2–4 mg/kg)
displayed paradoxical anxiogenic responses, but these effects
disappeared upon drug discontinuation. Using rats, it was shown
that adolescent fluoxetine (10 mg/kg) exposure resulted in
impaired visual discrimination, after a wash-out period of 14 days
[13]. Finally, In ˜iguez et al. [14] reported that exposure to
fluoxetine (10 mg/kg) from postnatal day (PND) 35 to 49 was
associated with decreased responsiveness to forced swimming
stress, increased sensitivity to natural reward and anxiety-eliciting
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Adult fluoxetine exposure alleviated the increased anxiety induced
by the adolescent fluoxetine [14], suggesting that adolescent and
adult fluoxetine exposure can have opposing effects. Collectively,
the literature on adolescent SSRI exposure in rodents is rather
mixed, with negative (no drug effect), beneficial (decreased stress
responsiveness) and adverse (increased sensitivity to anxiety-
eliciting conditions) outcomes.
The present study aimed to increase the understanding of the
age-related outcomes of adolescent fluoxetine exposure. Since the
mixed results reviewed above may be due to differential wash-out
periods and ages of testing, and the adverse effects of adolescent
fluoxetine exposure in humans are manifested particularly short
after the start of treatment [2;15], we specifically focussed on the
time period shortly after the wash-out of fluoxetine, when
neuroplastic changes may have established. We also aimed to
establish whether (nor)fluoxetine levels in rats were in the clinical
range, and to extend the behavioral repertoire sensitive to SSRI
treatment. Therefore, we not only included emotion-related tests,
but also tests for sensorimotor integration and sleep/wake patterns.
Finally, our goal was to shed light on potential neuroplastic changes
underlying the age-dependent effects of SSRIs. To these ends we
treated adolescent rats from PND 25 to 49, and adult rats from
PND 67 to 88, orally with 12 mg/kg fluoxetine, and tested the
animals 7–14 days later, when fluoxetine had been washed out. The
adolescent window we used approximates mid-childhood through
adolescence in humans [16–18]. The animals were tested in a series
of tests measuring emotional behavior, namely the open field test
(novelty-induced locomotor activity), elevated plus maze (EPM) test
(anxiety), forced swim test (behavioral despair), and the acoustic
startle response. In addition, sensorimotor integration (prepulse
inhibition; PPI) and sleep/wake behavior (electroencephalography)
were measured. We observed both harmful (behavioral despair; no
effectonwakefulness)andbeneficial(noanorexiceffect)outcomesof
fluoxetine treatment during adolescence compared to adulthood.
Age-dependent effects on the acoustic startle response and prepulse
inhibition were also observed, but not in the elevated plus maze test.
Exploratory behavior was not affected by fluoxetine.
There is accumulating evidence that SSRIs exert their effects
through neuroplastic changes (for review see [19–21]). Because the
adolescent brain is more plastic than the adult brain, differential
neuroplastic effects in adolescent and adult rats could underlie age-
dependent effects of fluoxetine. To elucidate some of the mechanisms
underlying our behavioral observations, we assessed plasma levels
of fluoxetine and the metabolite norfluoxetine. In addition, we
conducted a series of immunohistochemical stainings focussing on the
5-HT1A receptorandPSA-NCAMinthedorsalraphenucleus(origin
of serotonergic cell bodies), amygdala, and medial prefrontal cortex
(mPFC),brainareasplayingacentralroleinemotional,cognitiveand
sensory information processing and responsive to the (therapeutic)
effects of antidepressants [22–26]. The 5-HT1A receptor is strongly
implicated in the actions of SSRIs [27;28], and plays a role in
neuroplasticity as well [29]. PSA-NCAM is the polysialylated (PSA)
form of the neural cell adhesion molecule (NCAM) that is involved in
neurite and synaptic remodeling. It is modified by chronic fluoxetine
exposure in a region-dependent manner [25]. We observed that
amygdalarPSA-NCAM,butnot5-HT1A receptor,immunoreactivity
was differentially affected by fluoxetine in adolescent and adult rats.
Materials and Methods
Animals
All experiments were approved by the Committee for Animal
Experiments of the Radboud University Nijmegen Medical
Centre, Nijmegen, The Netherlands, and all efforts were made
to minimize animal suffering and to reduce the number of animals
used.
Wistar Unilever (WU) male rats (Harlan, Horst, The Nether-
lands) were 21 and 63 days of age at arrival. Since they were
obtained from the same experimental animal supplier and both
age groups arrived at the animal facility 4 days before the start of
the treatment, the background and history of both age groups was
similar. The animals were housed two per cage (MacrolonH
40625615 cm) in temperature controlled rooms (2062uC). After
4 days of acclimatisation, the rats were daily treated with 12 mg/
kg fluoxetine (Pharmacy Radboud University Nijmegen Medical
Centre) or 1% methylcellulose (Genfarma B.V. Maarssen, the
constituent of the fluoxetine pills that were used) by oral gavage for
21 days. Rats treated during PND 25–49 are referred to as the
adolescent group, and rats treated during PND 67–88 represent
the adult group. Body weight was monitored daily throughout the
treatment. From 7 days after the last injection the animals were
tested as described below. Separate groups of animals were used
for 1) the open field and elevated plus maze tests (10 adolescent
methylcellulose, 10 adolescent fluoxetine, 10 adult methylcellulose,
and 10 adult fluoxetine treated rats), 2) the acoustic startle/
prepulse inhibition and forced swim tests (10 adolescent methyl-
cellulose, 10 adolescent fluoxetine, 10 adult methylcellulose, and
10 adult fluoxetine treated rats), and immunohistochemistry (4
adolescent methylcellulose, 4 adolescent fluoxetine, 5 adult
methylcellulose, and 5 adult fluoxetine treated rats), and 3)
sleep-wake behavior and plasma (nor)fluoxetine levels (7 adoles-
cent methylcellulose, 7 adolescent fluoxetine, 7 adult methylcel-
lulose, and 7 adult fluoxetine treated rats). Consecutive tests were
separated by 2 days (see table 1 for time schedule). Housing and
testing (between 09.00 a.m. and 16.00 p.m.) took place under a
standard 12-hr day/night cycle (lights on at 07.00 a.m.), except for
animals in experimental group 3 (sleep/wake behavior), which
were housed directly after arrival in the animal facility under a
reversed day/night cycle (lights off at 07.00 a.m.) and were tested
over 24 hrs.
Surgery
Two weeks before testing, rats were implanted, under complete
anesthesia (isoflurane), with a standard cortical tripolar electroen-
cephalography (EEG) electrode set (Plastics One MS-333/2-A,
Plastic Products, Roanoke, VI, USA) and a bipolar electromyog-
raphy (EMG) electrode set (Plastics One MS 303/71). EEG
electrodes were placed in the frontal cortex and in the parietal
region, with coordinates A 2.0, L 3.5 and A 26.0, L 4.0,
respectively (with skull surface flat and bregma zero-zero; [30]),
while the third earth electrode was placed in the cerebellum. The
EMG electrode was subcutaneously placed in the dorsal neck
muscles. After surgery the rats were individually housed and
allowed to recover for two weeks.
Behavior
Novelty-induced locomotor activity. Novelty-induced loco-
motor activity was recorded by video tracking in PhenotyperH cages
(Noldus Information Technology, Wageningen, The Netherlands).
The cages (45645645 cm), made of transparent Perspex walls and
a black floor, were equipped with a feeding station and two drinking
bottles. Each cage had a top unit containing a built-in digital
infrared-sensitive video camera, infrared lighting sources, and
hardware needed for video tracking. The rats were placed in the
Phenotypercages[31]andtotaldistancemoved(cm)wasmonitored
for 1 hr.
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to a height of 50 cm with two open (50610; 2.5 lux) and two
enclosed (50610640; 0.2 lux) arms. As described earlier [32], rats
were allowed to freely explore the maze for 5 min. Behavior was
registered automatically by a computerized system (Plus Maze
,
Nijmegen, The Netherlands). Results were expressed as the mean
of time spent (s) in open arms.
Forced swim test. Cylindrical glass tanks (50 cm tall618 cm
diameter), filled to a depth of 30 cm with 22 (+/21)uC water, were
used. After a 15-min water experience on day 1, the animals were
tested 24 hrs later in the water cylinders for 5 min [32]. The
movements of the rats were videotaped for off-line measurement.
‘Immobility’ was defined as making no movements for at least 2
seconds or making only those movements that were necessary to
keep the nose above the water.
Startle response and PPI. The acoustic startle chambers
consisted of a Plexiglas tube (8.2 cm in diameter, 25 cm in length)
with a piezoelectric accelerometer mounted beneath the tube. The
acousticstimuliweredeliveredbythePSR2computersoftware,viaa
speaker that was placed 10 cm above the tube. The software
converted the accelerometer measurements into a digital signal. The
background noise was 70 dB. Each session started with 5 min
acclimatisation, followed by ten blocks of 5 trials consisting of one
120 dB startle stimulus (basal amplitude), a no stimulus condition,
and pre-pulse startle stimuli of 3, 5 or 10 dB above background
(delivered pseudo-randomly). The prepulseswerealways followed by
the 120 dB stimulus after 100 ms. All stimuli were delivered for
20 ms. The interval between each trial was 10/20 s. The startle
amplitude was calculated as an average of the 10 trials of the startle
trial and the three different prepulse trials.The %PPI wascalculated
as follows: 100 - (startle amplitude/basal startle amplitude)6100.
Analysis of wake/sleep patterns. Rats were kept in a
Perspex recording cage (30625635 cm) equipped with a passive
infrared movement detector (Lunar PR 360u ceiling mount PIR,
Rokonet Industries, U.S.A.) attached to the ceiling of the cage.
Rats, chronically provided with cortical EEG electrodes and
nuchal EMG electrodes, were connected to a swivel, which
allowed free movement in their recording cage. EEG and EMG
signals were amplified, band-pass filtered (EEG 1–100 Hz; EMG
1–1000 Hz), a notch filter eliminated 50 Hz, sampled at 256 Hz
and stored on disk with the aid of a WINDAQ data acquisition
system (DATAQ Instruments, Akron, OH, USA). We analyzed
4 hrs (17.30–18.30, 19.30–20.30, 5.30–6.30 and 7.30–8.30 hrs)
from each rat, using the WinDaq Waveform Browser (DATAQ q
Instruments, Akron, OH, UA). Sleep and wake states were visually
scored according to conventional criteria based on EEG and EMG
[33], supplemented by the PIR scores. Wakefulness was
characterized by a small amplitude, fast frequency EEG together
with a high amplitude and/or a rapidly changing EMG and or
PIR; non-REM sleep by a large amplitude, low frequency EEG
together with a moderate and relatively constant EMG and low
PIR; sleep spindles by a pattern of symmetrical rhythmic waves, a
waxing and waning morphology with round peaks and valleys and
a dominant frequency of 11–15 Hz, minimal duration 0.5 sec
[33]; whereas REM sleep was characterized by a low voltage, high
frequency EEG with predominant beta-theta activity, and a low
amplitude EMG (atonia with occasional twitches) and a low PIR
score. Reported is the time (minutes) spent in each state.
Measurement of Fluoxetine and Norfluoxetine in blood
plasma
Plasma collection. 5 hrs and 1 wk after the last fluoxetine
injection blood samples were collected in Microvette CB 300
(Sarstedt, Germany) tubes through a tail cut. Blood plasma was
obtained by centrifugation of the blood at 4uC at 4000 rpm for
15 min. Supernatant was stored at 220uC until use.
HPLC. 50–100 ml of the plasma samples, containing
fluvoxamine as internal standard, were extracted as described by
Duverneuil et al. [34]. The concentration of fluoxetine and
norfluoxetine was determined by HPLC, which has been des-
cribed previously [35]. The mobile phase consisted of a buffer
containing 20 mM citric acid and 20 mM phosphoric acid (pH
adjusted to 3.8 with NaOH) mixed with acetonitril (55:45).
Separation was performed at 32uC using a flow rate of 0.8 ml/
min. The concentration of each compound was calculated by
comparison with both the internal and external standards. The
limit of detection (signal/noise ratio 3:1) was 15 ng/ml in 100 ml
plasma samples.
Reagents. Norfluoxetine and fluoxetine were purchased from
Sigma, HPLC grade acetonitril and hexane from Biosolve B.V.
(Valkenswaard, The Netherlands), isoamylalcohol and hydrochloric
acid from Merck (Darmstadt, Germany), and sodiumhydroxide,
phosphoric acid and citric acid monohydrate were obtained from
Acros (Geel, Belgium).
Immunohistochemistry
7 Days following the forced swim test, rats of group 2 were
deeply anesthetized and perfused transcardially with 0.1 M PBS,
pH 7.3, followed by 400 ml 4% paraformaldehyde dissolved in
0.1 M PB, pH 7.2. Immunostaining was performed as previously
described [32], using 5-HT1A (1:250; Santa Cruz Biotechnology,
Santa Cruz, CA, USA), or PSA-NCAM (1:8.000; Millipore,
Billerica, MA, USA) antisera.
Quantification. Numbers of PSA-NCAM immunopositive
cells were quantified [26] using the software program Neurolucida
(MicroBrightfield Inc, Williston, VT, USA), and 5-HT1A
immunoreactivity was quantified using Image J, a public domain
image processing program (http://rsb.info.nih.gov/ij/) that
assessed the intensity of immunostaining [25]. Intensity was
corrected for background intensity, and expressed as relative
optical density (O.D.). Target areas included the dorsal raphe
nucleus (bregma 27.68 [30]), the basolateral amygdala (bregma
22.6 to 23.3; [30]) and mPFC (prelimbic cortex; bregma +4.68 to
+3.0; [30]). The latter two subregions were based on reported
Table 1. Time schedule of experiments.
5 hrs after last injection 7 days after last injection 10 days after last injection 14–17 days after last injection
Group 1 Open field Elevated plus maze
Group 2 Prepulse inhibition Forced swim test Immunohistochemistry
Group 3 Blood collection Blood collection EEG/EMG
Each group consisted of adolescent and adult rats treated with either fluoxetine or methylcellulose.
doi:10.1371/journal.pone.0016646.t001
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reactivity was assessed in homologous square fields (using a grid
overlay with a size of 1006100 mm) that displayed a representative
density of stained cells, at 20x magnification.
Statistical analysis
All statistical analyses were performed using SPSS version 16.0
(SPSS Inc., Chicago, IL, USA). Data were analyzed using one-way
ANOVA followed by Bonferroni post-hoc testing (time effect sleep/
wake behavior), two-way ANOVA (novelty-induced locomotor
activity, anxiety, behavioral despair, acoustic startle, PPI, immu-
nohistochemistry) or repeated measures ANOVA (sleep/wake
behavior, body weight). Interaction effects were further analysed
using two-way ANOVA (sleep/wake patterns) and Student t-tests.
Probability values of p,0.05 were considered significant. NS =
not significant.
Results
Bodyweight
The bodyweight of fluoxetine and methylcellulose treated
animals (group 1) across the fluoxetine/methylcellulose treatment
is shown in figure 1A (adolescents) and 1B (adults). Starting weight
was not different in the adolescent (t(1,18)=0.6, NS) and adult
(t(1,18)=0.474, NS) fluoxetine and methylcellulose groups. Repeat-
ed measures ANOVA revealed that fluoxetine had no effect
on body weight in adolescent rats (F(1,18)=0.826, NS), but signi-
ficantly reduced adult body weight (F(1,18)=9.218, p,0.01).
Independent Student t-tests indicated that the body weight
reduction in adults was significant (p,0.05) from day 11 of treat-
ment and further on. Similar results were obtained for group 2 and
3 (data not shown).
Novelty-induced locomotor activity
Two-way ANOVA revealed that total distance moved was
significantly higher in adolescent compared to adult rats (F(3,36)=
5.073, p,0.05). However, fluoxetine did not affect locomotor
activity (F(3,36)=0.687, NS) (figure 2), and no age x treatment
interaction was observed (F(3,36)=1.662, NS).
EPM
Fluoxetine significantly decreased open arm time in adolescent
and adult rats (F(3,36)=9.344, p,0.005), but there was no
significant age (F(3,36)=0.803, NS) nor age x treatment
(F(3,36)=0.17, NS) effect (figure 3).
Forced swim test
Adolescent rats spent less time on floating (immobility)
compared to adult rats (F(3,36)=12.544, p,0.001). Further, we
obtained a significant age x treatment interaction (F(3,36)=5.467,
p,0.05), but no significant treatment effect was observed
(F(3,36)=0.004, NS) (figure 4). A subsequent Student t-test for
time spent on immobility indicated that fluoxetine increased
immobility in adolescent rats (t(1,18)=2.107, p,0.05), but had no
effect in adults (t(1,18)=1.385, NS).
Startle response and PPI
Overall, the adult animals showed a higher startle reflex
compared to the adolescent rats (F(3,36)=49.006, p,0.0001), there
was a significant treatment (F(3,36)=4.570, p,0.05), and age x
treatment (F(3,36)=4.465, p,0.05) effect (figure 5A). A subsequent
Student t-test revealed that fluoxetine decreased the startle reflex
in adults (T(1,18)=2.138, p,0.05) but not in adolescents
(T(1,18)=0.731, NS).
When the animals were exposed to prepulse stimuli of 73 (PP3),
75 (PP5) or 80 (PP10) dB preceding the startling stimulus, four
animals had to be removed from the analysis because PPI scores
were negative. At PP3, PPI was higher in adult compared to
adolescent rats (F(3,32)=5.755, p,0.05), but no significant
treatment (F(3,32)=2.395, NS) or age x treatment (F(3,32)=1.956,
NS) effect was observed (figure 5B). Similar patterns were found
for PP5 [age: (F(3,34)=14.691, p,0.0001), treatment: (F(3,34)=
0.287, NS), age x treatment: (F(3,34)=0.711, NS)] and PP10 [age:
(F(3,32)=24.511, p,0.0001), treatment: (F(3,32)=1.900, NS), age x
treatment: (F(3,32)=1.304, NS)].
Sleep/wake behavior
3 Animals of the adult methylcellulose treated group were lost
due to technical problems. Analysis of the time spent in the awake
state across the four consecutive time points (figure 6A) revealed
no overall age (F(1,21)=1.900, NS), treatment (F(1,21)=0.168, NS)
and age x treatment interaction (F(1,21)=0.337, NS) effects, but the
time x age (F(3,21)=5.920, p,0.001) and time x age x treatment
interactions (F(3,21)=3.146, p,0.05) were significant. Posthoc
analysis of the time x age x treatment interaction indicated that
there were age x treatment interactions within the 17.30–18.30
Figure 1. Effect of fluoxetine on body weight in adolescent and adult rats. Data are presented as mean 6 S.E.M. body weight (g) in
adolescent rats (A) and adult (B) rats (n=10). 21 Days of fluoxetine treatment had no effect on bodyweight of adolescent rats, but reduced
bodyweight in adult rats.
*p,0.05 fluoxetine versus methylcellulose in age group.
doi:10.1371/journal.pone.0016646.g001
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p,0.05) intervals. The treatment effects in the 17.30–18.30
interval was significant for the adult (t(1,9)=2.809, p,0.05), but
not adolescent (t(1,9)=0.346, NS) rats. Thus, fluoxetine increased
the awake state in adult rats only. For the 19.30–20.30 interval
Student’s t-test did not reveal treatment effects for either the adult
or adolescent rats (t,1.9). An age effect was obtained for the
17.30–18.30 interval (F(3,21)=17.613, p,0.05), reflecting in-
creased time spent in the awake state in adolescent rats. Finally,
one-way ANOVA (using time as between-subject factor) revealed a
significant effect of time (F(3,96)=20.482, p,0.0001). According to
a subsequent Bonferroni post-hoc test time in the awake state was
significantly higher in the 17.30–18.30 interval compared to the
other intervals (p,0.005), and significantly lower in the 19.30–
20.30 interval compared to the 07.30–08.30 interval (p,0.005).
Non-REM sleep analysis revealed an overall age effect
(F(1,21)=4.587, p,0.05), without treatment (F(1,21)=0.115, NS)
and age x treatment effect (F(1,21)=0.034, NS) (figure 6B). Further,
the time x age (F(3,21)=6.794, p,0.0001) and time x age x
treatment interactions (F(3,21)=3.481, p,0.05) were significant.
Two-way ANOVA for each interval separately showed that the
time x age x treatment interaction was due to the 17.30–18.30
interval: a significant age x treatment (F(3,21)=5.455, p,0.05)
effect and age effect (F(3,21)=17.226, p,0.05) was obtained. A
Student t-test for the 17.30–18.30 interval showed that fluoxetine
decreased non-REM sleep in adult (t(1,9)=2.732, p,0.05), but not
adolescent (t(1,9)=0.657, NS), rats. The age x treatment interac-
tion for the 19.30–20.30 interval just missed significance
(F(3,21)=4.151, p=0.054). Finally, there was a significant time
effect (F(3,96)=22.005, p,0.0001), and post-hoc testing indicated
that time in non-REM sleep was significantly lower in the 17.30–
18.30 interval (p,0.005) and significantly higher in the 19.30–
20.30 interval (p,0.005) compared to the 05.30–06.30 and
07.30–08.30 intervals. There was no difference between the later
two intervals.
Regarding the time spent in spindles, there were no overall age
(F(1,21)=2.717, NS) and treatment (F(1,21)=0.553, NS) effects, but
the overall age x treatment interaction was significant (F(1,21)=
4.689, p,0.05) (figure 6C). Further, we obtained a significant time
x age x treatment interaction (F(2,21)=3.780, p,0.05). Subsequent
analysis revealed a strong trend for an age x treatment interaction
during the 19.30–20.30 interval (F(3,21)=4.264, p=0.051). No
time effect for spindles was observed (F(2,72)=0.537, NS).
Overall REM sleep analysis did not reveal age (F(1,21)=0.320,
NS), treatment (F(1,21)=0.604, NS) and age x treatment (F(1,21)=
0.598, NS) effects (figure 6D). There was a significant time x age
interaction (F(3,21)=3.615, p,0.05), and a subsequent two-way
ANOVA test for the separate intervals showed age effects for the
17.30–18.30 (F(3,21)=13.289, p,0.05) and 07.30–08.30 (F(3,21)=
5.232, p,0.05) intervals: REM sleep is reduced in adolescent rats
in the 17.30–18.30 interval, and increased in the 07.30–18.30
interval. Finally, a significant effect for time (independent of age or
treatment) was obtained (F(3,96)=11.406, p,0.05), and post-hoc
testing revealed that time in REM sleep was significantly lower in
the 17.30–18.30 and 07.30–08.30 intervals (p,0.005) compared
to the 19.30–20.30 and 05.30–06.30 intervals.
Figure 3. Effect of fluoxetine treatment on anxiety in
adolescent and adult rats. Data are presented as mean 6 S.E.M.
of time spent in the open of the elevated plus maze (n=10). 10 Days
following chronic fluoxetine treatment (12 mg/kg) anxiety in the
elevated plus maze test was increased in both adolescent and adult
rats.
#p,0.05 main treatment effect.
doi:10.1371/journal.pone.0016646.g003
Figure 4. Effect of fluoxetine treatment on behavioral despair
in adolescent and adult rats. Data are presented as mean 6 S.E.M.
of time spent on immobility (n=10). 10 Days following chronic
fluoxetine treatment (12 mg/kg) behavioral despair, expressed as
immobility in the forced swim test, was increased in adolescent, but
unaffected in adult rats.
ap,0.05 main age effect;
‘p,0.05 age x
treatment interaction;
*p,0.05 fluoxetine versus methylcellulose in age
group.
doi:10.1371/journal.pone.0016646.g004
Figure 2. Effect of fluoxetine on exploratory behavior in
adolescent and adult rats. Data are presented as mean 6 S.E.M.
of distance moved within 60 min (n=10). 7 Days following chronic
fluoxetine treatment (12 mg/kg) exploratory behavior in the open field
was not affected in adolescent, nor adult, rats.
ap,0.05 main age effect.
doi:10.1371/journal.pone.0016646.g002
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5 Hrs after the last fluoxetine injection fluoxetine was detected
at levels of 260614 ng/ml in adolescents and 375638 ng/ml in
adults (table 2). Norfluoxetine levels were 1.8 times higher in
adolescents (463655) and 2.9 times higher in adults (1069685). 1
Week after the last fluoxetine injection fluoxetine levels were below
the detection threshold.
Immunohistochemistry: 5-HT1A receptor and PSA-NCAM
in the dorsal raphe nucleus, mPFC, and amygdale
The relative optical density (O.D.) of 5-HT1A receptor
immunostaining in the dorsal raphe nucleus was not affected by
age (F(3,14)=0.035, NS), and fluoxetine treatment (F(3,14)=0.021,
NS; figure 7A). Neither an age x treatment interaction was
observed (F(3,14)=0.085, NS). Likewise, in the mPFC there were
Figure 5. Effect of fluoxetine treatment on the startle reflex and PPI in adolescent and adult rats. Data are presented as mean 6 S.E.M. of
the startle reflex (n=10; A) and PPI (n=9; B). 7 Days following chronic fluoxetine treatment (12 mg/kg) the acoustic startle response was reduced in
adult, but not adolescent rats. Fluoxetine had no significant effects on PPI.
ap,0.05 main age effect;
#p,0.05 main treatment effect;
*p,0.05
fluoxetine versus methylcellulose in age group.
doi:10.1371/journal.pone.0016646.g005
Figure 6. Effect of fluoxetine treatment on the awake state, non-REM sleep, spindles, and REM sleep in adolescent and adult rats.
Data are presented as mean 6 S.E.M. minutes time spent in the awake state (A), non-REM sleep (B), spindles (C), and REM sleep (D) (n=4–7). These
states were measured at four time intervals: 17.30–18.30 p.m., 19.30–20.30 p.m., 5.30–6.30 a.m. and 7.30–8.30 a.m. Rats were housed under a reversed
12 hr day/light cycle, with lights on at 19.00 p.m. 14–17 Days following chronic fluoxetine treatment (12 mg/kg) wakefulness was increased and non-
REM sleep was decreased in adult, but not adolescent rats during the 17.30–18.30 p.m. interval.
‘p,0.05 age x treatment interaction;
ap,0.05 age
effect;
*p,0.05 fluoxetine effect significantly different from methylcellulose effect.
doi:10.1371/journal.pone.0016646.g006
The Age-Dependent Effects of Fluoxetine
PLoS ONE | www.plosone.org 6 January 2011 | Volume 6 | Issue 1 | e16646no treatment (F(3,14)=0.576, NS) and age (F(3,14)=0.043, NS)
effects, and there was no significant age x treatment interaction
(F(3,14)=1.276, NS; figure 7B). In contrast, in the amygdala 5-
HT1A receptor immunostaining was decreased in adults rats
compared to adolescent rats (F(3,14)=39.566, p,0.0001), but there
were no treatment (F(3,14)=3.239, NS) or age x treatment interac-
tion (F(3,14)=1.236, NS; figure 7C) effects.
PSA-NCAM immunoreactivity in the dorsal raphe nucleus was
lower in adult compared to adolescent rats (age: F(3,14)=7.524,
p,0.05), but no treatment effect (F(3,14)=2.972, NS) or age x
treatment interaction (F(3,14)=0.003, NS) was observed (figure 8A).
In the mPFC no significant age (F(3,14)=2.977, NS), treatment
(F(3,14)=0.245, NS), and age x treatment (F(3,14)=0.66, NS) effects
were found (Figure 8B). Interestingly, in the amygdala we obtained
a significant treatment x age interaction (F(3,14)=6.123, p,0.05;
figure 8C) for PSA-NCAM. No further age (F(3,14)=0.328, NS)
and treatment (F(3,14)=0.227, NS) effects were found. A
subsequent Student t-test revealed that fluoxetine tended to
increase PSA-NCAM immunoreactivity in adolescent rats
(t(1,8)=1.503, NS) and tended to decreased it in adult rats
(t(1,8)=1.802, NS), but no significant effects were obtained.
Discussion
Here we show that fluoxetine exerts age-dependent effects:
adolescent, as opposed to adult, fluoxetine exposure resulted in an
increase in depression-like behavior. In addition, the beneficial
effect of fluoxetine on wakefulness was only seen in adult rats. On
the other hand, adolescent rats showed resilience to the anorexic
effects of fluoxetine [36;37]. The age-dependent behavioral effects
of fluoxetine are likely to be specific, because novelty-induced
locomotor activity was unaffected by fluoxetine in both age
groups. We tested the animals 7-14 days after the last fluoxetine
injection. Since fluoxetine was undetectable in blood plasma 1
week after the last injection, we argue that these behavioral
manifestations reflect neuroplastic changes. As such, PSA-NCAM
immunoreactivity in the amygdala at 17 days after the last
injection was differentially affected in fluoxetine treated adolescent
and adult rats. Given the central role of the amygdala in the
modulation of emotional responses [38], the age-dependent effects
of fluoxetine on anxiety- and depression-like symptoms may be
attributed to changes in amygdalar neuroplasticity.
Our findings correspond to the findings of Oh and colleagues
[12], who showed that juvenile mice treated with fluoxetine
displayed paradoxical anxiogenic responses. However, these
responses disappeared upon drug discontinuation, while the
anxiogenic response in our study was observed 1 week after drug
discontinuation. Unlike Oh and colleagues [12], we also observed
an anxiogenic response in adult rats. Increased anxiety on the
EPM test following chronic fluoxetine treatment has also been
reported by others [39;40]. In ˜iguez and colleagues [14] found in
Sprague-Dawley rats that anxiety on the EPM was increased at 1
day and 30 days of withdrawal from adolescent fluoxetine
exposure, suggesting that the anxiogenic effects of adolescent
fluoxetine exposure have a long-lasting nature. In ˜iguez et al. [14]
further reported that adolescent fluoxetine exposure was associ-
ated with antidepressant effects, while we observed depression-like
effects in the present study. Rats were treated at PND35–49 in the
study of In ˜iguez et al. [14] and at PND 25–49 in the current study.
It is plausible that the younger age in this study explains this
discrepancy, as neonatal (PND4-PND21) fluoxetine exposure also
leads to depression-like symptoms during adulthood [41]. Further,
given that fluoxetine plasma levels following a 10 mg/kg
intraperitoneal injection are approximately twice the blood levels
found following oral administration [42], injection route might
also explain the discrepancy. Moreover, it is possible that rat strain
Table 2. Fluoxetine (ng/ml) and norfluoxetine (ng/ml) levels in blood plasma.
AGE
Fluoxetine
5 hr after last injection
Fluoxetine
7 d after last injection
Norfluoxetine
5 hr after last injection
Norfluoxetine
7 d after last injection
Adult 375637 0 1069685 0
Adolescent 260614 0 463655 0
doi:10.1371/journal.pone.0016646.t002
Figure 7. The relative optical density of 5-HT1A receptor immunostaining in the dorsal raphe nucleus, mPFC, and amygdala of
fluoxetine and methylcellulose treated adolescent and adult rats. Data are presented as mean 6 S.E.M. of O.D. in the dorsal raphe nucleus
(A), mPFC (B), and amygdala (C) (n=4–5) per 1006100 mm. 14–17 Days following chronic fluoxetine (12 mg/kg) treatment no differences in 5-HT1A
immunostaining were found in the dorsal raphe nucleus, mPFC and amygdala. Yet, 5-HT1A receptor immunoreactivity was lower in adult compared to
adolescent rats in the amygdala.
ap,0.05 main age effect.
doi:10.1371/journal.pone.0016646.g007
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explain the differential outcomes. Finally, Norcross and colleagues
[10] reported that chronic adolescent fluoxetine exposure (3–7
weeks of age) in mice did not induce changes in anxiety- and
depression-like behavioral responses. Possibly species differences in
the pharmacology/metabolism of fluoxetine explain the discrep-
ancy between this study and ours.
While it has been well established that SSRIs decrease REM
sleep in both humans and rats [43–47], we found no changes in
REM sleep in the adolescent and adult rats. This may be
explained by the wash-out period in the present study, since the
REM sleep suppressive effects diminish after withdrawal from
chronic SSRI treatment within a few days, and in some of the
discontinuation nights a REM rebound was found [48;49]. In
addition, it is possible that the Wistar strain we used (WU) is
relatively insensitive to the REM sleep-reducing effects of
fluoxetine, given that there are rat strain differences regarding
sleep regulation [50]. Nonetheless, the sleep/wake pattern was
clearly affected by fluoxetine in adult rats, while it had no effects in
adolescent rats. The increased waking and decreased non-REM
sleep in the period before the lights were switched on (17.30–18.30
p.m.) suggests that wakefulness was increased, as has been shown
previously [49]. The differences occurred in the last hr of the dark
period, when the amount of non-REM sleep is rather low. During
the period in which deep non-REM sleep is prevalent, the light
period and especially the early hrs of the light period, there were
no differences between the age groups. The increased amount of
waking in adolescent rats agrees with the commonly reported age-
related changes in sleep quantity [51].
There was a significant decrease in basal startle response in the
fluoxetine-treated adult rats compared to the adult controls, an
effect that was not found in the adolescent rats. Shanahan and
colleagues [52] also reported a reduction in the startle response
upon chronic fluoxetine treatment in adult mice. Apparently, this
effect does not extend to adolescence, which indicates that the
pathway underlying the acoustic startle response and the stress
responses measured in the elevated plus maze and forced swim
tests differ. Yet, it should be noted that there could have been a
floor effect in adolescent rats, because their startle response under
control conditions was already low. Further, PPI was not
significantly reduced in adolescent and adult rats, which is in line
with previous observations in adult mice [52]. PPI is modulated by
a variety of 5-HT receptors, including the 5-HT1A, 5-HT1B, and
5-HT2A receptors [52–57]. We did not observe changes in 5-HT1A
receptor immunoreactivity in the amygdala. Although PPI is
mediated by several other brain areas, it could be one reason why
fluoxetine failed to significantly affect PPI.
5 Hrs after the last fluoxetine injection, the fluoxetine
concentration in blood plasma was 260614 ng/ml in adolescents
and 375638 in adults, which falls in the range of a low 50–60 to a
high 400–500 ng/ml reported in humans [58–61]. Body weight of
the fluoxetine adolescent rats was 220 grams and fluoxetine adult
rats 360 grams at the last treatment day, i.e. 5 hrs before blood
collection. Correction for body weight therefore reveals nearly
identical fluoxetine concentrations (adolescent 1.18 versus adult
1.04 ng/ml/gram body weight fluoxetine). In line with this, it has
been shown that pediatric brain levels of fluoxetine are not
significantly different from typical adult levels when corrected for
the effects of dose per mass [62]. Further, the norfluoxetine/
fluoxetine ratio in adolescents was 1.8, which approaches the 1.3–
1.5 ratio measured in humans [60]. The higher ratio of 2.9 in
adults may relate to a lower metabolism of norfluoxetine. Because
both fluoxetine and norfluoxetine (the most active metabolite of
fluoxetine [63] levels were below the detection threshold at the
time of behavioral testing we do not expect that the differential
norfluoxetine/fluoxetine ratio’s in adult and adolescent rats
affected the behavioral outcomes. It is therefore most likely that
the age-dependent effects of fluoxetine on behavior are due to
neuroplastic changes.
As reported previously [25], fluoxetine treatment in adult rats
tended to reduce PSA-NCAM immunoreactivity in the amygdala.
Interestingly, we show for the first time that fluoxetine tended
to increase PSA-NCAM immunoreactivity in adolescent rats.
Although these effects were not significant, the age x treatment
interaction was. Incorporation of PSA confers anti-adhesive pro-
perties to NCAM [64], which allows neurons to participate in
plastic events such as neurite outgrowth or synaptic reorganization
[65]. Varea and colleagues [25] showed that decreases in PSA-
NCAM following fluoxetine treatment were not correlated with
alterations in synaptophysin immunoreactivity in the basolateral
amygdala and mPFC. Synaptophysin is a marker for presynaptic
boutons, suggesting that the age-dependent neuroplastic effects
as we observed in the amygdala do not involve changes in
neurotransmitter release. As antidepressant treatment can prevent
amygdalar dendritic hypertrophy induced by chronic stress [66],
increased synaptic remodelling in adolescent fluoxetine exposed
Figure 8. PSA-NCAM immunoreactivity in the dorsal raphe nucleus, mPFC, and amygdala of fluoxetine and methylcellulose treated
adolescent and adult rats. Data are presented as mean 6 S.E.M. of the numer of immunoreactive neurons in the dorsal raphe nucleus (A), mPFC
(B), and amygdala (C) (n=4–5) per 1006100 mm. 14–17 Days following chronic fluoxetine (12 mg/kg) treatment the number of PSA-NCAM
immunoreactivity was lower in adult compared to adolescent rats, but only in the dorsal raphe nucleus. In addition, we obtained a significant age x
treatment interaction for PSA-NCAM immunoreactivity in the amygdala, which tended to be increased in adolescent, and decreased in adult rats.
ap,0.05 main age effect;
‘p,0.05 age x treatment interaction.
doi:10.1371/journal.pone.0016646.g008
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speculative at this point and the exact implications of our findings
thus remain to be investigated. Given that PSA-NCAM is
preferentially involved in neurite and spine outgrowth [67], it
would be of interest to study the morphological changes associated
with the age-dependent effects of fluoxetine. In contrast to
previous studies [25,26] we did not observe effects of chronic
fluoxetine treatment on PSA-NCAM immunoreactivity in the
mPFC. A potential explanation is the fact that our measurements
were conducted 2.5 weeks following the last fluoxetine injection,
while increases in fluoxetine-induced PSA-NCAM expression were
observed 1 day following chronic fluoxetine treatment [25,26]. In
the dorsal raphe nucleus we observed an age-dependent effect for
PSA-NCAM, in line with the idea that aging is associated with a
decrease in synaptic remodelling [68], although the adult rats in
the present study were still quite young. 5-HT1A receptor
immunostaining in the dorsal raphe nucleus, amygdala and mPFC
was not differentially affected by fluoxetine treatment. This finding
was somewhat surprising, given the role of the 5-HT1A receptor in
the antidepressant effects of SSRIs [27;28] and the interaction
between 5-HT1A receptor activation and PSA-NCAM immuno-
reactivity [29]. Yet, it does not exclude the involvement of the 5-
HT1A receptor, because we did not assess 5-HT1A receptor
function. We did observe that 5-HT1A immunostaining was lower
in adult rats compared to adolescents in the amygdala, which may
be in line with the region-independent decline in 5-HT1A receptor
immunoreactivity in mice and human during ageing [69]. But
again, our adult rats were relatively young. Finally, it has been
previously observed that the 5-HT3 receptor colocalizes with PSA-
NCAM in the prefrontal cortex, and that the 5-HT3 receptor
antagonist ondansetron reversed the effects of chronic fluoxetine
treatment on PSA-NCAM expression in the mPFC [26],
suggesting that the 5-HT3 receptor is an important target for
future research.
A possible limitation of the present study is that we used
commercial animals, both the adolescent and adult rats were
shipped 4 days before the start of the fluoxetine treatment. It is
conceivable that the adolescent rats were more shipping stress
sensitive than adult rats. Yet, given that the adolescent were more
active in the Phenotyper, were less immobile in the forced swim
test and showed a reduced acoustic startle response compared to
adult rats it is not a likely confounding factor. Nonetheless, having
more time for acclimatisation following shipping would have been
more ideal. Further, because we conducted two behavioral tests in
the same group of animals (see table 1) it is possible that stress
associated with the first test affected performance in the second
test. However, no relationship was found for fluoxetine effects in
adolescent and adults rats in the open field and elevated plus maze
tests. This was also true for the acoustic startle/PPI and forced
swim test data. Likewise, the absence of an anorexic effect in
adolescent rats was not indicative for reduced efficacy of fluoxetine
in these animals. Another issue is that immunohistochemistry was
executed on brains derived from animals that were orally treated
and tested in the acoustic startle/PPI and forced swim test.
Although stress induces neuroplastic changes, it is critical to note
that all animals received the same amount of stress. Notable is also
that we used healthy male rats for the present study. Although our
observations may correspond to reports in humans that fluoxetine
treatment in adolescents may paradoxically increase depression-
related behavior without notification of gender differences [4;7],
future research is needed to elucidate the age-dependent effects of
SSRIs in depression-related animal models as a function of sex.
Finally, due to some technical problems during cutting our sample
size for the immunohistochemical studies was rather small. Yet, we
obtained a significant age x treatment interaction effects and it was
clear that fluoxetine differentially affected PSA-NCAM immuno-
reactivity in adolescent and adult rats. It is also important to note
that the brains that had been cut correctly were not pre-selected
brains based on behavioral performance.
In conclusion, we show that adolescent fluoxetine exposure can
lead to an adverse increased depression-like outcome. In addition,
adolescents may not benefit from fluoxetine’s effects on wakeful-
ness. Vice versa, the anorexic effects of fluoxetine were not seen in
adolescent rats. These age-dependent effects of fluoxetine on
emotional behavior are most likely due to neuroplastic changes,
since amygdalar PSA-NCAM was decreased in adults, but
increased in adolescent rats. Together, the data importantly
contribute to the debate about the safety of SSRIs in adolescents
and the experiment set-up as used here may help in the
identification of the mechanisms underlying the age-dependent
effects of fluoxetine.
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